Johnson & Johnson (JNJ) reports Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.